We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Alkermes Begins Phase I Study on Immuno-Oncology Drug
Alkermes plc (ALKS - Free Report) announced the commencement of a multi-center phase I study on its immuno-oncology candidate ALKS 4230 (formerly known as RDB 1450). The study will evaluate the tolerability, safety and immunological-pharmacodynamic effects of ALKS 4230 for the treatment of patients with solid tumors.
Alkermes will conduct the study in two stages – a dose-escalation stage followed by a dose-expansion stage. The company expects interim data from the first stage of the phase I study are expected in 2017.
We note that competition in the immuno-oncology market is stiff given the presence of drugs like Opdivo, Keytruda and Yervoy among others.
Apart from ALKS 4230, Alkermes has a robust pipeline consisting of several candidates. Interesting candidates include ALKS 5461 (phase III – major depressive disorder), ALKS 3831 (phase III-schizophrenia), ALKS 8700 (phase III-multiple sclerosis and ALKS 6428 (phase III – to help physicians transfer patients from opioid agonists to antagonist therapy using Vivitrol).
Alkermes is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Retrophin, Inc. and Acorda Therapeutics, Inc. . While ANI Pharmaceuticals and Retrophin sport a Zacks Rank #1 (Strong Buy), Acorda Therapeutics carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. .Click to get this free report >>